It has been observed that the death due to COVID 19 infections is secondary to severe Pneumonia and systemic hyperinflammation.
Severe Pneumonia is a condition of Pneumonia, when support to the respiratory system is needed for its proper functioning.
Respiratory support may be in the form of oxygen inhalation or mechanical ventilation,invasive or non-invasive.
Systemic hyperinflammation is a state in which there is secretion of cytokines in huge amount,called cytokine storm.
These both conditions,severe Pneumonia and hyperinflammatory state carry highn mortality.
MAVRILIMUBAB is Granulocyte-monocyte colony stimulatinfg factor -receptor alpha ,monoclonal antibody with ability to check cytokine storm.
In a study at Italy,which is published in Lancet,authors studied on 39 patients who were non mechanically ventilated.They gave mavrilimubab intravenously to 13 patients in the dose of 6 mg/kg(single dose),in addition to standard care for Pneumonia. 24 patients received standard care for pneumonia and they acted as control.
8% patients in study group, progressed to mechanical ventilation as compared to 35% in control group(p=0.14)
During the follow up period of 28 days,non of the patients died in study group ,whereas 27% patients died in control group(p=0.086).
All patients (100%) showed clinical improvement in study group as compared to 65% in control group(p=0.03).Improvement was earlier in study group as compared to control group(p=0.0001).Fever control was faster in study group as compared to control group(p=0.0093).
Mavrilimubab was well tolerated with no infusion reaction,whereas 12% of control group developed infectious complications.
Study was done between March 15 and April 17,2020
SO,Mavrilimubab may be life saving in severe Pneumonia due to COVID19 and syudy on large sample is needed before its recommendation
REFERENCES;
De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study [published online June 16, 2020]. Lancet Rheumatol. doi:10.1016/S2665-9913(20)30170-3
TOPICS: COVID19 LUNG INFECTIONS PNEUMONIA
Get Pulmonology Advisor in Your Inbox
Sign up to get the latest pulmonology news in your inbox.
*E-mail Address
United States
Pulmonology Advisor Update
SIGN UP!
Registered users get free access to premium features like:
A personalized onsite experience
Your top three articles, curated onsite daily
Unlimited access to our expert content
REGISTER
Already have an account? Sign in here
Popular in Pulmonology
Patients With Elevated CRP in COVID-19 May Benefit From Steroid Therapy
Continuing Medical Education (CME/CE) Courses
Individualizing Therapy for Type 2 Diabetes Mellitus to Overcome Clinical Inertia: Clinical Case Vignettes
Cases and Commentaries in Atopic Dermatitis
Psychiatry Board Review
RME Hot Seat: Incorporating Personalized Treatment Into Severe Asthma Management